Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Hope they're worth the money. I do like the flapjacks, and find they work as intended. I can't understand why they always seem to be discounted. Surely they should do away with this "discounted" nonsense and just sell as it is ?
I think if it was a typo we would have had an amendment by now? I think we have been, through not actually knowing, guessing on the most skeptical percentages, but this rns from last year did state actual percentage royalties. It's hard to comprehend these figures and what it would mean for the company.
From last July's RNS;
A manufacturing agreement signed with a US partner in September 2020. They are paying OptiBiotix a six figure annual milestone in H2 every year during scale up plus a six figure launch milestone payment with royalties of 5% on all sales and a further 5% on sales to 11 named companies (Kelloggs, Nestle, Coca Cola , Firmenich, Tereos, Cargill, Arla ,Tate and Lyle, Agropur, Givaudan, Tata) reflecting the development work ongoing with these partners before we signed the agreement.
I can't understand the muted response to yesterdays Sweetbiotix news. Surely the numbers we're seeing here will lead to staggering revaluation of the company? procurementresource.com/resource-center/stevia-price-trends
Is it me, am I missing something obvious?
ProBiotix Health plc (AQUIS: PBX), a life sciences business developing probiotics to support cardiometabolic health, announces it has entered into a partnership agreement with SymbioPharm, a German company pioneering in microbiome research and knowledge-based probiotics. SymbioPharm has secured its position as a leading innovator and provider of probiotics, medicinal products and dietary supplements in Germany, Austria and Switzerland where it is considered a top tier consumer brand. SymbioPharm's distribution network spans direct-to-consumer channels as well as a comprehensive online and offline pharmacy presence.
The agreement allows SymbioPharm to utilise ProBiotix's CholBiome® CH formulation to target and reduce cholesterol in their branded consumer products. SymbioPharm has introduced the CholBiome® CH formulation as a premium pharmacy supplement solution across targeted regions. The agreement covers sales in Germany, Austria and Switzerland, focusing on maximising market penetration through strategic pharmacy partnerships.
The unique and innovative formulation developed by ProBiotix comes with a European Food Safety Authority (EFSA) health claim, specific for cholesterol.
Steen Andersen, CEO of ProBiotix Health plc commented: "We are delighted that Symbiopharm, a recognised leader in the probiotic space, has engaged with ProBiotix Health. This collaboration is strategically aligned with our goal of extending the reach of our unique finished product formulations within the DACH region (Germany, Austria and Switzerland). This is an important step for us to further expand our business in the consumer health segment, and allow us to reach a broader audience, enhancing market presence and influence."
Tobias Brodtkorb, CEO of SymbioPharm added: "We are very pleased to have entered into this agreement with ProBiotix Health. We are a collaborative business and are passionate about natural treatments using live bacteria. Our focus is not only on effective therapies, but also on the associated diagnostics and scientific research on the microbiome, and we find our model fits in naturally with ProBiotix and their mission. We are delighted to be working closely with them and hope for a strong relationship going forward."
I see Croda sp jumped up today. Someone must have got wind of the impending buy out by SBTX! Don't laugh, maybe SA is big mates with Elon?
Or, someone got wind of the blockbusting SBTX lysate?
Oh! Is it morning already? I must stop eating cheese before bedtime.
Hope it's a happy Christmas for us long suffering devotees.